Amarin Corporation plc (NASDAQ:AMRN) is reporting second quarter financial results on Tuesday 4th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, AMRN is expected to report 2Q20 loss of $ 0.07 per share from revenue of $ 149.48 million.
For the full year, analysts anticipate top line of $ 669.69 million, while looking forward to loss of $ 0.13 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 650.00 million ~ $ 700.00 million
Click Here For More Historical Outlooks Of Amarin Corporation plc
Previous Quarter Performance
Amarin Corporation plc unwinded loss for the first quarter of $ 0.06 per share, from the revenue of $ 154.99 million. The consensus estimates are loss of $ 0.07 per share from $ 137.43 million in revenue. The bottom line results beat street analysts by $ 0.01 or 14.29 percent, at the same time, top line results outshined analysts by $ 17.56 million or 12.78 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Amarin Corporation plc
Stock Performance
According to the previous trading day, closing price of AMRN was $ 6.77, representing a 71.39 % increase from the 52 week low of $ 3.95 and a 74.08 % decrease over the 52 week high of $ 26.12.
The company has a market capital of $ 2.61 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”AMRN” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Amarin Corporation plc will be hosting a conference call at 7:30 AM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.amarincorp.com
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The companys lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels.
